Search the Newsreel

Cue Biopharma (CUE) Q2 2024 earnings summary

Cue Biopharma announced a strategic corporate restructuring, including a 25% workforce reduction, to reduce capital requirements and prioritize autoimmune programs (CUE-401 and CUE-501) while continuing oncology programs. The company reported increased collaboration revenue, a reduced net loss for Q2 2024, and a cash runway …

Cue Energy Resources (ASX:CUE) Dividend Focus: Balancing Yield with Energy Market Cycles

Cue Biopharma (NASDAQ:CUE) Stock Price Down 0.7% - Here's Why

Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie

Cue Biopharma, Inc. has granted its Chief Medical Officer, Dominique Christian Borie, 31,500 restricted stock units (RSUs) and stock options for 63,000 shares. The stock options have an exercise price of $30.92 per share and expire in 2036. Both the RSUs and stock options …

Cue Biopharma (NASDAQ: CUE) CMO Dominique Borie files initial Form 3

Cue Biopharma, Inc. (NASDAQ: CUE) Chief Medical Officer Dominique Borie has filed an initial Form 3, an SEC filing used to report the beneficial ownership of securities by company insiders. The filing indicates no reported share transactions or derivative exercises by Borie, signifying an …

Fortescue (ASX:FMG) Dividend Story Heats Up as Income Appeal Returns

Fortescue (ASX:FMG): High Dividend Yield—Opportunity or Warning Sign?

Is the Fortescue share price a buy for its 8% dividend yield?

Are Fortescue Ltd (ASX:FMG) shares good value in 2026?

Cue Biopharma Stock Falls 3.27%: Support Tested as Biotech Sector Weighs - Wyckoff Distribution

New Cue Biopharma CEO lines up $30M to advance allergy, autoimmune drugs

Cue Biopharma earnings beat by $2.22, revenue topped estimates

Fortescue (ASX:FMG) Stock Analysis: High-Yield Dividend and Annual Returns Backed by Record Output

Can Fortescue (ASX:FMG) Maintain Growth After Record Iron Ore Shipments and Encouraging Earnings?

Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Autoimmune drug program nets Cue Biopharma $15M cancer therapy deal

Cue Biopharma earnings beat by $0.10, revenue topped estimates

Here's the earnings forecast out to 2030 for Fortescue shares

How do experts view Fortescue, Ebos Group and Woodside Energy shares after earnings?

Fortescue delivers record shipments and a bigger dividend in H1 FY26 earnings

Fortescue (ASX:FMG) share price rises as net profit jumps 23% in HY26 result

Those who invested in Cue Energy Resources (ASX:CUE) three years ago are up 155%

There's No Escaping Fortescue Ltd's (ASX:FMG) Muted Earnings

Cue Biopharma Stock Drop Looks Sharp, But How Deep Can It Go?

Is Cue Biopharma (NASDAQ:CUE) Using Debt In A Risky Way?

Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights

LLYC alcanza un beneficio neto de 9 millones de euros en 2024 y marca un nuevo récord

Cue Biopharma (CUE) Stock Price, News & Analysis

Investors in Cue Biopharma (NASDAQ:CUE) have unfortunately lost 83% over the last three years

Cue Energy Resources Limited (ASX: CUE) - Financials

Cue Energy Resources Limited (ASX:CUE) - Shares, Dividends & News

Cue Biopharma (CUE) Earnings Date and Reports 2026 $CUE